What a Peptide Cycle Actually Is
Best vendor for BPC-157 right now: Amino Club
10mg vial, $39.99 per vial ($4.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendorsA cycle is a defined block of administration followed by a defined break. The concept is simple; the useful question is why anyone would run one, and whether any evidence says how long it should be.
Calculate your draw for any compound on this page
Pick the peptide, enter your vial, water and dose, and get the exact syringe mark plus doses per vial. Twenty-seven compounds, free, no signup.
Open the peptide calculator peptulator.com, the Bureau's independent toolMuch of the cycling advice in peptide communities is borrowed from anabolic steroid habits, where the break is usually described as a way to let the body's own hormone production restart. Peptide secretagogues work differently: they stimulate the body's own release rather than replacing it, so the steroid reasoning does not carry over directly (the wider comparison is in peptides vs steroids). Cycle length then depends on the individual compound, and for most of them nobody has tested it.
What the Evidence Does and Does Not Show
In the sources checked for this page, no human trial compared one peptide cycle schedule with another. What exists is narrower: how long particular trials ran, and what happened when treatment stopped. The table puts those results next to the cycle lengths reported in community protocols so the two are not confused. Community figures are reported, not recommended.
| Compound | Longest human trial checked | What it showed about stopping or continuing | Community cycle, as reported |
|---|---|---|---|
| Semaglutide 2.4 mg | 68 weeks, then a one year off-treatment extension (327 participants) | After withdrawal, participants regained 11.6 percentage points of the 17.3% they had lost, about two thirds of the loss | Not cycled |
| Tirzepatide | 36 week lead-in, then 52 weeks randomised (670 participants) | Switched to placebo, weight rose 14.0% from week 36 to week 88; continuing, it fell a further 5.5% | Not cycled |
| Tesamorelin | 26 week main phase plus 26 week extension, daily injections (HIV with abdominal fat) | Visceral fat reduction held for 52 weeks on treatment and fat built back up after stopping; the label sets no fixed treatment length | Prescription product, not a research cycle |
| Hexarelin | 16 weeks, twice daily injections (12 healthy older adults) | GH response fell from 19.1 to 10.5 (area under the curve) and was 19.4 four weeks after stopping | 4 to 6 weeks on, 4+ weeks off |
| MK-677 | 12 months of 25 mg daily (65 older adults, part of a 2 year trial) | GH and IGF-I rose to young adult levels; fasting glucose rose 0.3 mmol/L (5 mg/dL) on average and insulin sensitivity decreased. Breaks were not tested | 8 to 16 weeks on, 4 to 8 weeks off |
| BPC-157 | No controlled human trial found; a 2025 review counted 35 preclinical studies and 1 clinical study | The one clinical study was retrospective: 7 of 12 patients reported relief for over 6 months after a single knee injection. No clinical safety data | 4 to 8 weeks on |
| Ipamorelin | Single 15 minute infusions in healthy men (8 per dose level) | Pharmacokinetics and GH response to one dose. No repeated dosing or cycle study among the sources checked | 8 to 12 weeks, or continuous |
Two things follow. First, the only measured on and off pattern in this set is desensitization of a growth hormone releasing peptide, and even that is partial. Second, for the drugs that have withdrawal trials, stopping reverses much of the effect, which is why they are not cycled. Every other number on this page is convention: sometimes sensible, but untested.
The Three Legitimate Reasons to Cycle
Almost every defensible cycling decision traces back to one of three reasons, and knowing which one applies tells you the cycle length without having to look it up.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes1. Receptor Desensitization
Repeated stimulation of a receptor can reduce its density or its signalling responsiveness, so the same dose produces a smaller effect over time. This is the genuine, mechanism level reason to cycle and it applies mainly to the growth hormone releasing peptides. Hexarelin is the best documented example: in a 16 week study of twice daily injections in 12 healthy older adults, the growth hormone response was significantly lower at week 4 and week 16, and had returned to its starting level when tested 4 weeks after the last dose. The authors described the attenuation as partial and reversible. That recovery is where the commonly quoted four week minimum break comes from.
2. A Finite Biological Endpoint
Some peptides are run to accomplish a task rather than to maintain a state. The reasoning is that once a tendon repair has plateaued, further dosing adds nothing. That logic assumes the peptide speeds repair in people, which human trials have not shown (see the table above), so treat the endpoint as a reason people give, not a finding.
3. Uncertainty About Long Term Safety
For compounds with no long term human safety data, which is most of this space, limiting cumulative exposure is a precaution some people take. It is the weakest reason in mechanistic terms and the most honest one in practice. Cycling for this reason does not make a compound safer; it only limits how long any unknown effect has to build.
Cycle Length by Peptide Class
The table below summarises the cycle lengths reported across the main classes in community protocols. These are reported practice, not trial results and not recommendations; the evidence table above shows which have any trial behind them.
| Class | Examples | Reported on | Reported off | Cycling Driver |
|---|---|---|---|---|
| Healing and repair | BPC-157, TB-500 | 4 to 8 weeks | 4 weeks or until reassessment | Finite endpoint |
| Non selective GHRPs | Hexarelin, GHRP-2, GHRP-6 | 4 to 6 weeks | 4+ weeks | Desensitization |
| Selective GHRPs | Ipamorelin | 8 to 12 weeks or continuous | Optional, 2 to 4 weeks | Precaution only |
| GHRH analogs | Sermorelin, CJC-1295 | 3 to 6 months or continuous | Rarely needed | Precaution only |
| Oral secretagogues | MK-677 | 8 to 16 weeks | 4 to 8 weeks | Metabolic drift |
| Metabolic (GLP-1 class) | Semaglutide, tirzepatide | Ongoing | Not cycled | Effect reverses on stopping |
| Longevity | Epithalon, MOTS-c | 10 to 20 days | 3 to 6 months | Pulsed by protocol design |
| Cosmetic and topical | GHK-Cu | 8 to 12 weeks | Optional | Finite endpoint |
What these cost at Amino Club
List prices on 2026-09-08, before any code; Amino Club is the vendor Bureau readers order from most. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
BPC-157 10mg · $39.99 Ipamorelin 10mg · $49.99Healing and Repair Peptides
BPC-157 and TB-500 are the two compounds most often cycled, usually for four to eight weeks. The reason given is the time soft tissue repair takes, but that number was not derived from a trial. A 2025 systematic review of BPC-157 found 35 preclinical studies and a single small retrospective clinical study, and reported that no clinical safety data exist. In animal models BPC-157 improved outcomes in muscle, tendon, ligament and bone injury; those results have not been reproduced in controlled human trials. We found no data on receptor desensitization for either compound, so a break is not justified on that ground.
People who use these compounds usually describe the endpoint as functional rather than calendar based: stop when the problem has resolved, and question the diagnosis if nothing has changed after several weeks. Evidence and realistic timelines for the underlying conditions are covered in the guide to peptides for tendon repair and peptides for joint pain. Schedules for running the two together, and the reasoning behind the pairing, are in the Wolverine stack guide and TB-500 vs BPC-157, so they are not repeated here. If you are comparing sources for a block, the BPC-157 buying guide lists what we check.
One caveat: a mechanical cause of an injury, such as load or technique, is not something any peptide cycle addresses.
Growth Hormone Secretagogues
This is the class where a mechanism-based reason to cycle has human data, and where the compounds differ more than the class label suggests.
The Desensitizing End
A review of the human work on growth hormone releasing peptides describes partial desensitization, more during continuous infusion and less with intermittent dosing. That fits the hexarelin results: in a 16 week study the response fell from 19.1 to 10.5 (area under the GH curve) and was back at 19.4 after four weeks off, while an earlier study of intermittent hexarelin (8 days intranasal, 15 days oral, in older adults) found no desensitization. For GHRP-2, a series of 7 to 30 day studies found that whether the response desensitizes depends partly on dose and frequency. The commonly quoted community blocks, 4 to 6 weeks for hexarelin and around 8 to 12 weeks for GHRP-2 and GHRP-6, are reported practice; we could not trace the GHRP-2 and GHRP-6 figures to a trial.
The Less Studied End
Ipamorelin is described as selective for the growth hormone pathway, and the case for running it without breaks rests on that selectivity. The human data we could open are single dose pharmacology, so "minimal desensitization" is an assumption rather than a measured result; the ipamorelin guide and ipamorelin dosage page cover what is known. GHRH analogs are the exception with real duration data: tesamorelin was given daily for 26 weeks and then a 26 week extension in its label studies, and the label sets no fixed treatment length. For sermorelin and CJC-1295, continuous use is a community pattern, set out in the sermorelin dosage guide.
A Layered Structure Described in Community Protocols
- Base: a GHRH analog run continuously for 3 to 6 months
- Layer: a GHRP added in defined 4 to 6 week blocks
- Break: the GHRP is withdrawn while the base continues
- Rationale given: only the compound thought to desensitize gets cycled. No trial has tested this layout
MK-677 Is a Different Problem
MK-677 is an oral secretagogue. In the 12 month, placebo controlled trial in 65 healthy older adults taking 25 mg daily, growth hormone and IGF-I rose to young adult levels, fat free mass rose 1.1 kg against a 0.5 kg fall on placebo, and body weight rose 2.7 kg against 0.8 kg. Fasting glucose rose an average 0.3 mmol/L (5 mg/dL), insulin sensitivity decreased, and mild transient leg swelling and muscle pain were the most frequent side effects. That metabolic drift is the usual argument for scheduled breaks, and the 8 to 16 week blocks are community practice: the trial itself ran continuously and did not test breaks. More in the MK-677 guide.
Whichever compound is used, the class level side effect picture and what is worth monitoring is set out in the peptide side effects guide.
Metabolic Peptides: The Class That Is Not Cycled
GLP-1 and dual agonist drugs are the clearest exception to the cycling framework, and they are the class with the best human evidence about stopping.
The Wegovy label lists "maintain weight reduction long term" among its uses. In the STEP 1 extension, people who stopped semaglutide 2.4 mg after 68 weeks regained 11.6 percentage points of the 17.3% they had lost within a year, about two thirds, and the cardiometabolic improvements moved back towards baseline. In SURMOUNT-4, people who switched from tirzepatide to placebo gained 14.0% in body weight over 52 weeks, while those who continued lost a further 5.5%; 89.5% of the continuing group kept at least 80% of their earlier loss, against 16.6% on placebo. A repeated on and off schedule would be expected to repeat that pattern of loss and regain, though no trial has tested that exact schedule.
These drugs do have a titration schedule, which is sometimes mistaken for cycling. The Wegovy label starts at 0.25 mg weekly and escalates every 4 weeks (0.25, 0.5, 1, 1.7 mg) to the 2.4 mg maintenance dose, to reduce gastrointestinal side effects, not to time a break. Details are in the semaglutide dosage guide, the tirzepatide dosage guide and the page on tirzepatide maintenance dose.
Longevity and Cosmetic Peptides
Longevity compounds follow their own convention, and it is short. The community protocol for epithalon is a 10 to 20 day course, repeated once or twice a year, rather than continuous dosing; the epithalon guide sets out the details. We did not open the original studies behind that schedule and found no controlled trial of it, so the length is reported practice. It is intermittent by design rather than because of a desensitization finding.
Topical GHK-Cu for skin is commonly reported at 8 to 12 weeks, with results judged at the end of a block. We did not verify a source for that duration. Where these fit in a broader approach is covered in top peptides for anti-aging and the GHK-Cu guide.
Structuring the Off Period
The only off period with measured data is the hexarelin one: after 16 weeks of twice daily injections, the GH response had recovered four weeks after stopping. That is the basis for four weeks as a floor for the non selective GHRPs. The wider rule that the break should be as long as the block is a community rule of thumb with no trial behind it, and a one week break after a six week block has not been shown to restore anything.
For healing peptides, people use the break differently: three to four weeks without the compound is a way to see whether an improvement holds on its own. That is a reasonable use of a break, but the interval is a convention.
What to Do During the Break
- Keep the non cycling components running. In the layered structure above, the base continues while the GHRP is withdrawn.
- Take the measurement. Bloodwork, a strength or range of motion test, or photographs. A break without data is a gap rather than a phase.
- Store the remaining vials properly. A four week break can outlast a reconstituted vial. The peptide storage guide covers the temperature and shelf life detail.
- Reconstitute fresh on restart rather than resuming on a vial that has sat for a month. Procedure is in how to reconstitute peptides.
Common Cycling Mistakes
- Treating a forum number as a finding. "Eight weeks on, four weeks off" circulates as universal advice. The evidence table shows which numbers have a trial behind them: very few.
- Cycling a GLP-1 drug. The withdrawal trials show most lost weight returning after stopping.
- Off periods too short to matter. The one measured recovery took four weeks after 16 weeks of dosing; a one week break has no data behind it.
- Starting several compounds at once. If three peptides begin on the same day, no side effect can be attributed to any of them. Introducing one at a time is a common precaution.
- Never recording anything. Without a baseline measurement, the end of a cycle produces an impression rather than a result.
A structured way to lay out compound selection and block timing before starting is available in the stack builder.
Frequently Asked Questions
How long should you cycle peptides?
No trial has established a cycle length for most research peptides, so any figure is community practice. Commonly reported blocks are 4 to 8 weeks for BPC-157 and TB-500, 4 to 6 weeks for hexarelin and 8 to 16 weeks for MK-677. The one measured on and off pattern is hexarelin: in a 16 week study the growth hormone response fell, and it had recovered 4 weeks after the last dose. GLP-1 drugs are not cycled, and their trials ran 68 to 88 weeks.
Do all peptides need to be cycled?
No. The only mechanism with human data is partial desensitization of the growth hormone releasing peptides, which a review of the human work found to be greater with continuous infusion than with intermittent dosing. Semaglutide and tirzepatide are used continuously, and the tesamorelin label sets no fixed treatment length. For BPC-157, TB-500 and ipamorelin we found no human trial of a cycle, so whether a break helps is unknown.
How long should the off period be?
The only measured figure is four weeks. After 16 weeks of twice daily hexarelin the growth hormone response had fallen from 19.1 to 10.5 (area under the curve), and four weeks after stopping it measured 19.4. The rule that the break should be as long as the block is a community rule of thumb without trial support. For healing peptides, people use a break of a few weeks to see whether an improvement holds, which is a convention and not a tested interval.
Is there any evidence for peptide cycling schedules?
Very little. A 2025 systematic review of BPC-157 found 35 preclinical studies and one small retrospective clinical study, with no clinical safety data. For ipamorelin the human data checked were single dose pharmacology. The best duration data are for approved drugs: tesamorelin for 26 weeks plus a 26 week extension, semaglutide for 68 weeks and tirzepatide for 36 plus 52 weeks. Those trials tested continuing against stopping, not on and off schedules.
Can you run more than one peptide in the same cycle?
Stacks are common in community protocols, for example a GHRH analog with a GHRP added in blocks. No trial has tested which combinations or schedules work better. The usual practical advice is to introduce one compound at a time, a week or more apart, so a side effect can be traced to one product. That is sensible but it is not evidence based.
Do you lose the results when a cycle ends?
For the drugs with withdrawal trials, largely yes. A year after stopping semaglutide 2.4 mg, participants had regained 11.6 percentage points of the 17.3% they had lost. In SURMOUNT-4, switching from tirzepatide to placebo raised body weight by 14.0% over 52 weeks, while continuing lowered it a further 5.5%. In the tesamorelin extension, visceral fat built back up after treatment stopped. For BPC-157 and TB-500 we found no human data on what happens after a block ends.
Is peptide cycling the same as steroid cycling?
No. Steroid cycles are usually described around suppression of the body's own hormone production, with the break meant to let it recover. Peptide secretagogues stimulate the body's own release, and the documented concern is receptor desensitization, so the steroid logic does not transfer directly. Cycle lengths for peptides are not derived from steroid trials.
Sources (checked 3 November 2026)
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab, 2022. PMID 35441470. Checked 3 November 2026.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024. PMID 38078870. Checked 3 November 2026.
- Novo Nordisk, Wegovy (semaglutide) prescribing information, revised 06/2026: indications, dosage escalation Table 1. novo-pi.com. Checked 3 November 2026.
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 2008. PMID 18690162. Checked 3 November 2026.
- EGRIFTA SV (tesamorelin) prescribing information, DailyMed (revised 2/2024; page updated 29 July 2026). DailyMed. Checked 3 November 2026.
- Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab, 1998. PMID 9589671. Checked 3 November 2026.
- Ghigo E, Arvat E, Gianotti L, et al. Short-term administration of intranasal or oral hexarelin does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol, 1996. PMID 8921821. Checked 3 November 2026.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol, 1997. PMID 9186261. Checked 3 November 2026.
- Bowers CY, Granda-Ayala R. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab, 1996. PMID 8887169. Checked 3 November 2026.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med, 2008. PMID 18981485. Checked 3 November 2026.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J, 2025. PMID 40756949. Checked 3 November 2026.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res, 1999. PMID 10496658. Checked 3 November 2026.
Community cycle lengths quoted on this page are reported practice and have no source in this list. Percentages and figures from the trials are as stated in each abstract or label, with one derived number: the roughly 45% fall in the hexarelin response in the answer at the top is (19.1 minus 10.5) divided by 19.1.